UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2018
AXOGEN, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Minnesota |
| 001-36046 |
| 41-1301878 |
(State or other jurisdiction of |
| (Commission File Number) |
| (IRS Employer Identification No.) |
13631 Progress Boulevard, Suite 400, |
| 32615 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code
|
(386) 462-6800 |
(Former name or former address if changed since last |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 28, 2018, AxoGen, Inc. (“AxoGen”) issued a press release announcing its financial results for the
quarter and year ended December 31, 2017. A copy of the press release is furnished as Exhibit 99.1 to this
Current Report.
The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits
Exhibit No. |
| Description |
99.1 |
| AxoGen, Inc. press release, dated February 28, 2018. |
EXHIBIT INDEX
|
|
|
Exhibit No. |
| Description |
99.1 |
| AxoGen, Inc. press release, dated February 28, 2018. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| AXOGEN, INC. |
|
|
|
Date: February 28, 2018 | By: | /s/ Gregory G. Freitag |
|
| Gregory G. Freitag |
|
| General Counsel & Senior VP of Business Development |